Fig. 1.

Flow scheme of AI approaches along with antiviral activity verification assays. Two independent datasets were compiled as the learning inputs to generate two AI prediction models of different approaches. Firstly, Model 1 was generated form the known drugs with antiviral activities. Model 2 was generated form the 3C-like protease inhibitors. A database for the market-approved drugs were adopted in which the AI system screens for potential drugs with antiviral activities. The AI-predicted drugs were verified with antiviral activities by a cell-based FIP virus replication assay. Finally, these assay results served as feedbacks for the AI relearning and evolution progress. The Modified AI model was established to screen further and again verified by the FIP virus replication assay. The processing flows are indicated with the arrows.